Chapter 70: Anxiety Disorders and Post-Traumatic Stress Disorder

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

So picture this.

Your 2 p .m.

patient is sweating profusely, their heart rate is hovering around like 130, they're dizzy, and they are absolutely convinced they're having a massive fatal heart attack right there in your exam room.

Oh, wow.

Yeah, that's a stressful presentation.

Right.

But you run the EKG and it is completely normal.

The troponin levels are totally fine, their oxygen saturation is perfect.

So what do you do next?

Well, you have to completely pivot your entire clinical mindset.

You're moving from a cardiac emergency to a psychiatric one.

And the tricky part is you have to do it without making the patient feel like you're dismissing their very real,

very terrifying physical symptoms.

Because those symptoms are deeply physiological, even if the root cause is psychiatric.

Welcome to this deep dive into the source material.

If you are an advanced practice nursing student gearing up for clinicals or studying for your board exams, this one -on -one tutoring session is specifically for you.

It's great to be here.

We are diving deep into chapter 70, anxiety disorders and post -traumatic stress disorder from primary care, the art and science of advanced practice nursing.

And our mission today is to take all that dense pathophysiology, the diagnostic criteria and the management plans and really just translate them into clear clinical reasoning.

Which is so needed.

I mean, we really have to reframe how we view anxiety in the clinical setting.

The text points out that 31 % of adults and adolescents will experience an anxiety disorder in their lifetime.

31%.

That is massive.

Right.

And we're not talking about everyday stress or like the temporary worry of an upcoming exam.

We're talking about a persistent biological disruption to a patient's functioning.

Approximately 56 % of adults with an anxiety disorder show moderate to serious impairment.

Which means early evidence -based intervention by the APN can literally change lives, but, you know, you can't assess what you don't understand biologically.

So let's lay down the foundational science before we even look at a diagnostic screener.

Let's talk about the HPA axis, the hypothalamic -pituitary -adrenal axis, and the amygdala.

Yes, the biological blueprint.

I hear the amygdala constantly compared to a smoke detector, but honestly that feels a bit passive to me.

To me, in an anxiety disorder, the amygdala acts more like an overzealous bouncer at a nightclub.

Oh, I love that analogy.

Right.

Like, the bouncer is supposed to look for actual threats, but instead his calibration is totally off.

He's hypervigilant, scanning the room and initiating a full -blown lockdown just because someone sneezed.

That is exactly it.

It highlights the action -oriented nature of the response.

The bouncer perceives a threat, signals the hypothalamus, and the HPA axis immediately floods the body with cortisol and adrenaline.

The sympathetic nervous system is just entirely hijacked.

So the fascinating clinical question here is, you know, who trained that bouncer to be so aggressive in the first place?

Well, it's highly multifactorial.

Genetics play a huge baseline role.

Having a first -degree relative with an anxiety disorder significantly increases your risk.

But the environment actively alters that biological wiring.

Yeah, the text highlights the Adverse Childhood Experience, or ACE, study here.

Exposure to childhood trauma during those critical developmental windows profoundly affects health outcomes through epigenetics.

Yes, specifically DNA methylation.

Right.

So the child's actually genetic code doesn't change, but the trauma causes methyl groups to attach to the DNA strands, essentially flipping the off switch on genes that are supposed to regulate stress.

The environment physically alters the expression of the biology.

Which is wild.

And that brings us to a crucial clinical tool outlined in Box 70 .2, psychopharmacogenetic testing.

Because genetics and epigenetic expression vary so wildly, APNs often face this really brutal trial -and -error phase when prescribing psych meds.

Oh, yeah.

Try this.

Come back in six weeks.

Try that.

It's awful for the patient.

Exactly.

So this testing helps reduce that guesswork by predicting two distinct physiological factors.

Pharmacokinetics and pharmacodynamics.

Let's break those down.

So pharmacokinetics refers to what the body does to the drug.

The genetic swab looks at the CYP450 enzymes in the patient's liver.

Imagine you prescribe a standard dose of an SRI to a patient who is genetically an ultra -rapid metabolizer.

Right.

Their liver enzymes destroy the medication before it ever reaches therapeutic levels in the brain.

They get zero relief.

And conversely, a poor metabolizer will build up toxic levels of the drug on that exact same standard dose, experiencing severe adverse side effects.

Then you have pharmacodynamics, which is what the drug does to the body.

Even if the pharmacokinetic profile is perfect and the right amount of medication actually reaches the brain, the patient might have a genetic variation in their serotonin receptors.

So the drug arrives, but the lock and key just don't fit.

Precisely.

The genetic test maps the patient's specific phenotype, allowing the APN to select a medication that targets the correct sequence.

It's an incredibly powerful tool, though it's always just one piece of a comprehensive clinical assessment.

And that comprehensive assessment absolutely relies on solid, evidence -based screening.

The text provides a great toolkit for the APN.

For adults, we utilize the GAD -7 to quantify anxiety severity, the PHQ -9 for depression, and the PHQ -15 to assess somatic symptoms.

And because psychiatric comorbidities are incredibly high, these are often combined into the PHQ -SEDA screener.

Right.

And if you are dealing with pediatric populations, the pathophysiology is similar, but the presentation is different.

So you'll utilize age -appropriate tools like the PARAS, the SCAR tool, or the EM -5.

And a key takeaway here.

You should never screen for anxiety in a vacuum.

If a patient's score is highly for anxiety, the APN must screen for depression and trauma.

Left untreated, those overlapping conditions will just sabotage any management plan.

Okay, let's apply this biology to the most broad presentation an APN will encounter in primary care, which is generalized anxiety disorder, or GAD.

Diagnostically, GAD is characterized by excessive, difficult -to -control worry persisting for at least six months.

Biologically, functional MRIs of patients with GAD show immense variability in the limbic system and the prefrontal cortex.

The neurochemistry involves a really complex shift.

We see disruptions in gamma -aminobutyric acid, right, GABA.

Yeah, GABA, which is the brain's primary inhibitory neurotransmitter.

It's essentially the brain's braking system, and in GAD, the brakes are failing.

We also see dysregulation of serotonin and norepinephrine.

Okay, but the mechanism that totally blew my mind in this chapter was the role of neuroinflammation.

The text points to emerging evidence linking reduced monoamine availability to pro -inflammatory cytokines.

Oh, this part is fascinating.

Right.

When a patient is in a state of chronic systemic inflammation, those inflammatory cytokines actually cross the blood -brain barrier, and they hijack the brain's tryptophan pathway.

Yep.

So instead of using tryptophan to synthesize serotonin, which is your mood -stabilizing neurotransmitter, the brain is tricked into producing quinolenic acid.

Which is neurotoxic and actually induces more anxiety.

It completely changes how we view psychiatric health.

The brain and the immune system are in constant communication.

And this systemic biological disruption explains why patients rarely walk into a primary care clinic and state, I have generalized anxiety disorder.

Oh, never.

They always present with somatic complaints.

They book an appointment for unexplained muscle tension, severe chronic fatigue, GI issues like nausea and irritable bowel symptoms, tension headaches, or intractable insomnia.

The anxiety is wearing a physical mask.

Exactly.

And this brings us to box 70 .3, the differential diagnosis, which is arguably the highest stakes moment for the APN.

You cannot simply hand a patient a psychiatric diagnosis without ruling out physiological mimics.

You absolutely cannot.

The symptoms of GAD overlap heavily with potentially life -threatening medical illnesses.

The clinical reasoning here requires a rigorous, really systematic approach.

Right.

So you must order standard blood chemistry, a comprehensive metabolic panel, an ECG and thyroid function tests.

Because hyperthyroidism, for example, forces the body into a state of sympathetic overdrive that looks identical to anxiety.

You also have to rule out congestive heart failure and arrhythmias.

And you must evaluate for respiratory issues like COPD or hypoxia, where the patient's physical air hunger manifests as psychiatric panic.

You even have to consider rare endocrine tumors like a pheochromocytoma.

Yeah, those episodically dump massive amounts of catecholamines into the bloodstream.

It looks just like a panic attack.

A full medication and substance review is also totally mandatory.

A patient's severe anxiety might actually be a direct pharmacological side effect.

Excessive use of albuterol inhalers, which are beta agonists, literally stimulate the body's fight or flight receptors.

Corticosteroids, theophyllin, massive caffeine intake, or withdrawal from alcohol or sedatives.

All of these can perfectly mimic GAD.

So once organic medical causes are confidently ruled out, the APN develops a patient -centered management plan.

Health promotion and non -pharmacological interventions are first line.

Cognitive behavioral therapy, or CBT, and structured mindfulness practices have demonstrated efficacy comparable to pharmacotherapy.

And this is where interprofessional collaboration really shines.

The APN manages the medical home, but refers out to licensed clinical social workers or psychologists for targeted CBT.

When moving to pharmacotherapy, the first line medications for GAD are SRIs and SNRIs, but the text includes a major prescribing caveat here.

The APN must provide thorough patient education about the delayed mechanism of action.

Yes.

These medications do not work immediately.

The downregulation of receptors takes weeks.

Initially, SRIs can actually cause medication -induced activation like jitteriness, nausea, increased anxiety.

And if the APN fails to warn the patient about this, the patient will inevitably stop taking the medication after a few days, fully convinced the drug is making their condition worse.

Setting expectations and utilizing a slow titration to a therapeutic dose secures patient compliance.

Absolutely.

But in the interim, while waiting weeks for the SRI to become therapeutic, the APN can utilize short -acting medications to bridge the gap.

Hydroxazine, which is an antihistamine with sedating properties, or gabapentin, can be highly effective.

The text specifically warns against jumping straight to benzodiazepines, though.

Yes.

Strongly warns against it.

While they work rapidly for acute symptom management, they carry severe risks for long -term dependence,

tolerance, and paradoxical reactions.

They should be strictly avoided in patients with any history of a substance use disorder.

Okay, so we've covered the chronic, simmering hyperarousal of GAD.

The biological bouncer is constantly on edge.

Let's shift our focus to panic disorder, which is what happens when that bouncer completely locks down the club, bypasses the logical prefrontal cortex entirely, and initiates a full -blown physiological survival response.

The presentation of panic disorder is terrifyingly acute.

Diagnostically, these are recurrent, unexpected episodes of intense fear that peak within minutes.

And to meet the criteria, the patient must experience four or more specific symptoms, right?

Right.

Palpitations, shortness of breath, a feeling of choking,

diaphoresis, dizziness, or a profound overwhelming fear of dying or losing control.

The structural imaging of the brain during a panic attack actually shows pathological involvement in the temporal lobes and the hippocampus.

But the mechanism that APNs really must understand is cerebral vasoconstriction.

Yes.

During a panic attack, the patient hyperventilates.

Blowing off too much carbon dioxide leads to respiratory alkalosis.

The shift in blood pH causes the blood vessels in the brain to literally constrict.

And that mechanism explains the physical symptoms perfectly.

The decreased cerebral blood flow directly causes the dizziness, the lightheadedness, and that terrifying feeling of unreality or derealization.

Exactly.

And this is the key to validating the patient.

Once you've medically cleared them, you use this physiology as a therapeutic intervention.

You explain you felt like you were passing out because the blood vessels in your brain were temporarily constricting due to rapid breathing.

You demystify the terror.

You rebuild their self -efficacy by proving their body isn't failing.

Their alarm system just misfired.

Which breaks the cycle of anticipatory anxiety, that constant fear of having another attack.

Looking at box 70 .4 and 70 .5 for management, CDT remains a first -line intervention, specifically targeting the cognitive distortions associated with those physical symptoms.

And pharmacologically, we utilize SRIs again, but there's a vital, totally board testable rule for the APN to remember here.

Yeah, the half -dose rule.

Yes, the half -dose rule.

Patients with panic disorder are exquisitely sensitive to medication side effects.

Right, because the normal activating side effects of an SRI, like the slight nausea, the increased heart rate, the jitteriness, they mimic the exact physical onset of a panning attack.

Precisely.

If you start them on a standard clinical dose, their brain interprets the side effect as a new attack and they will abandon the treatment immediately.

So the guideline is to start at half the recommended dose and titrate upward very slowly over several days.

The ultimate goal is full remission, maintaining treatment for 12 to 24 months.

Now, while panic attacks are defined by their unexpected nature, our next diagnostic category is highly specific.

Phobias involve a marked, disproportionate fear or anxiety attached to a specific object or situation.

Like needles, blood, specific animals, or flying.

The fear is so intense it causes active life -altering avoidance.

And the pathophysiology of a phobia relies heavily on classical conditioning.

The sympathetic hyperarousal gets permanently paired with a neutral stimulus.

And what's fascinating from a clinical perspective is that the patient's prefrontal cortex knows the fear is irrational.

They logically know a house spider isn't going to kill them.

But the amygdala just overrides the logical brain anyway.

Right.

And we shouldn't expect patients to always have a neat and tidy origin story for their phobia.

A phobia can develop from a direct negative experience, sure, but often the etiology is unknown and begins in childhood.

Because the fear is learned, the management is almost entirely non -pharmacological, focusing on unlearning the response.

The gold standard treatment is exposure therapy, which is a specific modality of FDT.

It works through the mechanism of habituation.

The therapist systematically desensitizes the patient to their triggers.

And it isn't just about getting used to it.

No.

The controlled exposure literally forces the amygdala to rewire its neural pathways, learning that the stimulus is actually safe, eventually extinguishing the conditioned, sympathetic response.

Which is why medications play a very limited role here.

Daily SRIs might be used to manage an underlying baseline of generalized anxiety.

Short courses of benzodiazepines are strictly reserved for rare, acute, and completely unavoidable triggers.

Like, for instance, a patient with a severe flying phobia who absolutely must board a plane to attend a funeral.

Exactly.

Just for those rare, unavoidable moments.

Okay.

So we've traced the pathology from chronic worry to unexpected panic to targeted avoidance.

Finally, let's examine what happens when the anxiety is read in a severe, life -threatening event that overwhelms the system's ability to cope.

Let's discuss post -traumatic stress disorder, or PTSD.

PTSD develops after a person witnesses or experiences direct exposure to actual or threatened death,

serious injury, or sexual violence.

Diagnostically, we must distinguish it from acute stress disorder.

Right.

For a formal PTSD diagnosis, the trauma -related symptoms must persist for more than 30 days post -trauma.

And the physiological brain changes are profound here.

Magnetic resonance imaging actually shows a physical decrease in the volume of the hippocampus and the left amygdala alongside chronic dysregulation of the HPA axis.

Because the hippocampus acts as the brain's filing cabinet, right?

It timestamps memories.

When it shrinks and malfunctions due to trauma, the traumatic memory doesn't get filed away as a past event.

It flutes in the system, feeling as though it is happening right now.

The biological fight, flight, or freeze response just gets stuck in the on position.

And the text organizes the clinical presentation into four distinct diagnostic symptom clusters.

Understanding these clusters is essential for the APN's assessment.

The first cluster is intrusion.

This isn't just remembering the event.

It is the persistent re -experiencing of the trauma through vivid flashbacks, nightmares, or severe physiological distress when exposed to reminders.

Then the second cluster is avoidance.

Patients will actively alter their lives to stay away from places, people, or even internal thoughts and conversations that act as reminders of the trauma.

The third cluster involves alterations in cognition and mood.

Patients report feeling completely detached from others, an inability to experience positive emotions, emotional numbness, or they harbor profoundly distorted feelings of guilt and self -blame regarding the event.

And the final cluster is alterations in arousal and reactivity.

This manifests as extreme hypervigilance and exaggerated startle response, irritable behavior, or reckless and self -destructive actions.

When we look at pharmacological management, the first line medications are again SSRIs and the SNRI venlafaxine.

But chapter 70 details a highly specific targeted intervention for the intrusive nightmare symptoms of PTSD that really highlights the beauty of clinical pharmacology prozosin.

Oh, prozosin is fascinating.

It's traditionally an alpha -1 adrenergic antagonist, a blood pressure medication.

In PTSD,

patients experience massive surges of noradrenaline in the brain during REM sleep.

This adrenergic storm is what causes those terrifying, vivid trauma nightmares.

And because prozosin crosses the blood -brain barrier, it can block those alpha -1 receptors in the central nervous system, effectively quieting the adrenergic storm and allowing the patient to sleep.

Exactly.

Additionally, trazodone is frequently utilized off -label to manage trauma -related insomnia.

However, the clinical guidelines heavily emphasize that non -pharmacological management is the true cornerstone of PTSD treatment.

The APN should facilitate referrals for trauma -focused psychotherapies over other generalized treatments.

The text highlights prolonged exposure, cognitive processing therapy, and EMDRI movement desensitization and reprocessing.

These therapies are rooted in emotional processing theory.

PTSD symptoms thrive on avoidance.

Avoiding the traumatic memories gives them power and prevents the hippocampus from processing them.

Right.

Prolonged exposure utilizes techniques like imaginal exposure, where the patient safely and repeatedly imagines and describes the trauma and its associated emotions.

Yes.

By systematically blocking cognitive avoidance, the therapy forces the brain to process and reorganize the memory, moving it from a current, active threat to a categorized past event.

It is essentially structural remodeling for the brain.

So what does this all mean for you, the APN student?

Let's trace the clinical reasoning thread of our deep dive.

That's a lot of information to synthesize.

It really is.

We started by grounding anxiety in biology, exploring the HPA axis, the ACE study, and how pharmacogenomics can guide our prescribing.

We identified how GAD often wears a somatic mask, requiring rigorous differential diagnosis to rule out physiological mimics like hyperthyroidism or respiratory alkalosis.

We broke down the cerebral vasoconstriction of panic disorder and the vital half -dose SRI rule.

We examined the targeted classical conditioning of phobias.

And finally, we explored the hippocampal changes in PTSD,

mapping the four symptom clusters and detailing how targeted medications like prezocin and therapies like prolonged exposure basically rewrite the trauma response.

Your ability to execute a comprehensive assessment, conduct a thorough medication review, and provide collaborative, patient -centered education, that is what transforms this dense pathophysiology into actual healing.

Absolutely.

And we want to leave you with a final thought drawn directly from the text.

As advanced practice nurses, you do not treat isolated biological systems.

You treat complex human beings living in a complex society.

The text notes that structural societal inequities, lower socioeconomic status, and chronic exposure to racial and ethnic discrimination directly contribute to the baseline rates of anxiety.

These systemic factors are heavily associated with a more severe, chronic course of PTSD in marginalized populations.

So how might recognizing and addressing those upstream factors, those structural inequities, change the way you formulate your treatment plans, collaborate with social services, and advocate for your patients?

Integrating that awareness into your clinical reasoning really elevates your practice from simply managing symptoms to truly providing holistic, transformative care.

Thank you so much for joining us for this session.

Your dedication to understanding the underlying mechanisms of these disorders is exactly what leads to exceptional, evidence -based care.

Keep studying hard, trust your clinical reasoning, and from all of us here, a warm thank you from the Last Minute Lecture team for listening.